ImmunoGen, Inc. (IMGN) financial statements (2021 and earlier)

Company profile

Business Address 830 WINTER ST
WALTHAM, MA 02451
State of Incorp. MA
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
6/30/2016
6/30/2015
6/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments294176262267245278142
Cash and cash equivalents294176262267245278142
Receivables0925252
Inventory, net of allowances, customer advances and progress billings   1133
Inventory   1133
Deferred costs    21 
Other undisclosed current assets3024143554
Total current assets:324209279276255292151
Noncurrent Assets
Operating lease, right-of-use asset1416
Property, plant and equipment671315231614
Deferred costs    64 
Other noncurrent assets11444310
Total noncurrent assets:31261718322215
TOTAL ASSETS:355235295295287314165
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities43334437332812
Accounts payable10101191285
Accrued liabilities291421171011 
Employee-related liabilities5912111187
Deferred revenue290
Debt23     
Deferred revenue and credits11402
Contract with customer, liability0
Other undisclosed current liabilities484126181587
Total current liabilities:122777156613621
Noncurrent Liabilities
Long-term debt and lease obligation192422100  
Long-term debt, excluding current maturities 222100  
Operating lease, liability1922
Liabilities, other than long-term debt8312885103304563
Deferred revenue and credits99264159
Deferred revenue81127
Contract with customer, liability80
Other liabilities3144444
Other undisclosed noncurrent liabilities41821271521781986
Total noncurrent liabilities:14323421425730824368
Total liabilities:26631128431336927990
Stockholders' equity
Stockholders' equity attributable to parent90(76)11(18)(82)3576
Common stock2211111
Additional paid in capital1,4191,2101,1931,009771743723
Accumulated deficit(1,332)(1,287)(1,183)(1,029)(854)(709)(648)
Total stockholders' equity:90(76)11(18)(82)3576
TOTAL LIABILITIES AND EQUITY:355235295295287314165

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
6/30/2016
6/30/2015
6/30/2014
Revenues1328253115608660
Revenue, net441913
Cost of revenue
(Cost of Goods and Services Sold)
   (1)(1)(1)(1)
Gross profit:1328253114598459
Operating expenses(155)(174)(215)(174)(185)(140)(131)
Other undisclosed operating income   1111
Operating loss:(22)(92)(161)(59)(125)(54)(72)
Nonoperating income (expense)15330(1)0
Investment income, nonoperating1441000
Other nonoperating income (expense)01(1)1(0)(1)0
Interest and debt expense(0)(0)(0)(26)   
Other undisclosed loss from continuing operations before equity method investments, income taxes     (5) 
Loss from continuing operations before equity method investments, income taxes:(21)(87)(158)(82)(125)(61)(71)
Other undisclosed loss from continuing operations before income taxes(23)(17)(11)(14)(20)  
Net loss available to common stockholders, diluted:(44)(104)(169)(96)(145)(61)(71)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
6/30/2016
6/30/2015
6/30/2014
Net loss:(44)(104)(169)(96)(145)(61)(71)
Comprehensive loss, net of tax, attributable to parent:(44)(104)(169)(96)(145)(61)(71)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: